---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-066953"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:09.216703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q4 revenue $160.8M (+32% YoY); net income $105.4M includes $83.8M tax benefit

## Summary
- Q4 revenue $160.8M (+32% YoY); full-year revenue $605.5M (+37% YoY).
- Net income $105.4M in Q4 ($2.62 diluted EPS); full-year net income $190.3M ($4.87 diluted EPS). Both include one-time tax benefit from valuation allowance release.
- U.S. OCS cases 5,139 in FY2025 (+38% YoY); owned 22 aircraft as of Dec 31, 2025.
- FY2026 revenue guidance $727M-$757M, representing 20% to 25% growth over FY2025.
- Appointed Giovanni Cecere as CCO, Amanda Sorrento as SVP HR, Matthew Forsyth as SVP GC; FDA approved OCS ENHANCE Heart and DENOVO Lung trials.

## SEC filing metadata
- accession: 0001193125-26-066953
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000119312526066953/0001193125-26-066953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000119312526066953/tmdx-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-066953
- JSON: https://secwatch.observer/filing/0001193125-26-066953.json
- Plain text: https://secwatch.observer/filing/0001193125-26-066953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.